L Gianni Selected Research

L Gianni Research Topics

Disease

27	Breast Neoplasms (Breast Cancer) 01/2024 - 09/2000
19	Neoplasms (Cancer) 12/2022 - 06/2000
5	Diarrhea 01/2019 - 11/2002
5	Cardiotoxicity 03/2003 - 01/2001
3	Triple Negative Breast Neoplasms 11/2022 - 12/2021
3	Ovarian Neoplasms (Ovarian Cancer) 01/2016 - 01/2013
2	Pathologic Complete Response 01/2022 - 12/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2013 - 02/2009
2	Asthenia 02/2009 - 03/2007
2	Vomiting 02/2009 - 03/2007
2	Nausea 02/2009 - 03/2007
2	Heart Failure 06/2001 - 01/2001
1	Adenocarcinoma 11/2017
1	Disease Progression 01/2016
1	Carcinoma (Carcinomatosis) 01/2016
1	Inflammatory Breast Neoplasms 10/2011
1	Thrombocytopenia (Thrombopenia) 03/2010
1	Sarcoma (Soft Tissue Sarcoma) 05/2009
1	Anemia 02/2009
1	Mucositis 02/2009
1	Motion Sickness (Airsickness) 10/2005
1	Infections 03/2004
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2004
1	Febrile Neutropenia 03/2004
1	Exanthema (Rash) 11/2002
1	Acne Vulgaris 11/2002
1	Stomach Neoplasms (Stomach Cancer) 08/2001

Drug/Important Bio-Agent (IBA)

7	Trastuzumab (Herceptin)FDA Link 10/2016 - 01/2001
7	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2009 - 01/2001
6	Paclitaxel (Taxol)FDA LinkGeneric 10/2001 - 06/2000
5	ErbB Receptors (EGF Receptor)IBA 12/2022 - 01/2002
5	pertuzumabIBA 01/2019 - 01/2013
4	Monoclonal AntibodiesIBA 01/2016 - 01/2002
4	Fluorouracil (Carac)FDA LinkGeneric 03/2003 - 08/2000
3	Methotrexate (Mexate)FDA LinkGeneric 01/2024 - 01/2001
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2024 - 01/2001
3	Gemcitabine FDA Link 11/2017 - 12/2001
3	Docetaxel (Taxotere)FDA Link 12/2015 - 06/2001
3	taxaneIBA 06/2010 - 06/2001
3	AnthracyclinesIBA 08/2001 - 01/2001
2	Hormones (Hormone)IBA 01/2024 - 12/2022
2	olaparibIBA 12/2022 - 08/2014
2	Progesterone Receptors (Progesterone Receptor)IBA 12/2021 - 04/2008
2	PlatinumIBA 08/2014 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2013 - 01/2001
2	Carboplatin (JM8)FDA LinkGeneric 01/2013 - 12/2001
2	Tamoxifen FDA LinkGeneric 10/2005 - 01/2001
2	Gefitinib (Iressa)FDA Link 11/2002 - 01/2002
2	Tyrosine Kinase InhibitorsIBA 11/2002 - 01/2002
2	cremophor ELIBA 10/2001 - 06/2000
1	Poly Adenosine Diphosphate RiboseIBA 12/2022
1	atezolizumabIBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 12/2021
1	Metformin (Glucophage)FDA LinkGeneric 04/2019
1	Loperamide (Imodium)FDA LinkGeneric 01/2017
1	Lapatinib (GW572016)FDA Link 10/2016
1	Immunoglobulin G (IgG)IBA 10/2016
1	GlycopeptidesIBA 01/2016
1	EpitopesIBA 01/2016
1	PankoMab-GEXIBA 01/2016
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2015
1	1-dodecylpyridoxal (PLD)IBA 08/2014
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2013
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2013
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2013
1	TrabectedinIBA 05/2009
1	Cadherins (E-Cadherin)IBA 04/2009
1	lipoplatinIBA 02/2009
1	human ERBB2 proteinIBA 04/2008
1	Estrogen ReceptorsIBA 04/2008
1	Proteins (Proteins, Gene)FDA Link 04/2008
1	CamptothecinIBA 03/2007
1	AntiemeticsIBA 03/2007
1	ST 1481 (Gimatecan)IBA 03/2007
1	Ciprofloxacin (Cipro)FDA LinkGeneric 03/2004
1	7-methylthiomethylpaclitaxel (BMS 184476)IBA 03/2004
1	Leucovorin (Folinic Acid)FDA Link 03/2003
1	Cisplatin (Platino)FDA LinkGeneric 03/2003
1	DNA (Deoxyribonucleic Acid)IBA 01/2002
1	Platinum Compounds (Compounds, Platinum)IBA 12/2001
1	Vinorelbine (Navelbine)FDA LinkGeneric 12/2001
1	adriamycinolIBA 06/2001
1	TubulinIBA 06/2001
1	Taxoids (Taxanes)IBA 05/2001
1	Epirubicin (Ellence)FDA LinkGeneric 04/2001
1	Indicators and Reagents (Reagents)IBA 01/2001
1	Humanized Monoclonal AntibodiesIBA 01/2001

Therapy/Procedure

15	Drug Therapy (Chemotherapy) 01/2023 - 08/2000
9	Therapeutics 12/2022 - 01/2001
4	Adjuvant Chemotherapy 01/2024 - 11/2000
3	Neoadjuvant Therapy 01/2022 - 02/2001
2	Radiotherapy 03/2003 - 09/2000
1	Immunotherapy 11/2022
1	Withholding Treatment 11/2002
1	Combination Drug Therapy (Combination Chemotherapy) 12/2001
1	Intravenous Infusions 10/2001
1	Radical Mastectomy 01/2001
1	CMF regimen 01/2001